TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 39nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Synblia Therapeutics
US Patent
Synblia Therapeutics
US Patent
Affinity DataIC50: <50nMAssay Description:IC50 values were determined at room temperature in 384-well black polystyrene plate, using a final reaction volume of 15 μl and the following as...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetMitogen-activated protein kinase kinase kinase 7/TGF-beta-activated kinase 1 and MAP3K7-binding protein 1(Homo sapiens (Human))
Zobio
Curated by ChEMBL
Zobio
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of recombinant human full-length His-tagged TAK1-TAB1 fusion protein (437 to 504 residues) expressed in baculovirus expression system usin...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair
TargetEctonucleotide pyrophosphatase/phosphodiesterase family member 2(Homo sapiens (Human))
X-Rx
US Patent
X-Rx
US Patent
Affinity DataIC50: <500nMAssay Description:The efficacy of the Examples described herein, as inhibitors of ATX are demonstrated and confirmed by pharmacological in vitro assays. The following ...More data for this Ligand-Target Pair